BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 24, 2014
View Archived Issues
Voyant Biotherapeutics and Allergan enter R&D agreement in ocular disease
Read More
German group patents novel antibodies for Plasmodium infections
Read More
Unbiased screening of chemotherapeutic agents used to uncover novel indications for existing drugs
Read More
Japanese researchers present new agents for neurological disorders and cancer
Read More
Discovery of a novel variant in a gene of unknown function associated with fatty liver disease
Read More
SCY-078 receives QIDP designation from the FDA
Read More
EMA concludes review of Protelos/Osseor
Read More
Novel FGFR inhibitors disclosed by Incyte Corp.
Read More
Scientists at Boehringer Ingelheim divulge novel BTK inhibitors
Read More
Janssen begins phase III CREDENCE study of canagliflozin in diabetic nephropathy
Read More
New vasopressin V1b receptor antagonists patented by Japanese group
Read More
Isis Pharmaceuticals reports data on ISIS-SMNRx in children with spinal muscular atrophy
Read More
Bristol-Myers Squibb discloses new agents for HIV infection
Read More
Cathepsin G detrimental in a subset of mice with ischemic stroke
Read More
Emergent BioSolutions' acquisition of Cangene complete
Read More
New phase Ib study evaluates ONT-380 with Kadcyla in metastatic HER2-positive breast cancer
Read More
Tender offer for NuPathe shares completed by Teva Pharmaceutical
Read More
FDA extends PDUFA action date for Ruconest
Read More
FDA extends approval of Kalydeco for cystic fibrosis mutations
Read More
Dosing completed in phase II trial of GCS-100 for chronic kidney disease
Read More
FDA grants 3-year exclusivity to Vascepa
Read More
Jazz Pharmaceuticals completes tender offer for Gentium shares
Read More
FTY-720 show anti-inflammatory effects on cerebral ischemia-reperfusion in vivo
Read More
Intra-arterial verapamil demonstrates neuroprotective properties in ischemic stroke model
Read More